Intentar ORO - Gratis

Why global pharma companies choose India for GCCs

BioSpectrum Asia

|

August 2024

India’s pharmaceutical industry is globally recognised for its capabilities in research and manufacturing and for its skilled labour. The country’s attractiveness as a destination for Global Capability Centres GCCs) is underpinned by several key factors, including cost-efficiency, a vast talent pool, robust infrastructure, and strong regulatory support.

- Anil Matai

Why global pharma companies choose India for GCCs

India serves as a key global hub for development, attracting investments of more than $7 billion. Global pharmaceutical companies have established GCCs in India which serve as centres of excellence for drug discovery, formulation development, and healthcare solutions, while also supporting a strong ecosystem by employing talent and increasing the knowledge base.

For instance, Novartis has had a significant footprint in India since 1947, and in the last two decades, it has evolved to be an integral part of the development journey of many breakthrough medicines in various therapeutic areas like cardiovascular, oncology, immunology, neurology, and ophthalmology, amongst others. Similarly, MSD is primed to support the Indian government in protecting every woman through HPV vaccination with nearly 85 per cent of their products being manufactured locally. In India, Novo Nordisk is conducting phase 2-4 clinical trials across major disease areas with over 3,000 enrolled patients. With 37 ongoing trials in various therapy areas, India accounts for 7-8 per cent of Novo Nordisk's global patient pool. As GCCs have evolved to become centres for innovation and research, India has transformed into a hub for new product development for global enterprises. Consequently, over 50 per cent of the world's GCCs are now located in India, driven by factors that provide a competitive edge for businesses aiming to optimise operations and drive innovation.

Cost-efficiency of conducting business

India offers a compelling cost-quality ratio, making it financially advantageous for companies to establish their GCCs in the country. Labour costs in India are significantly lower than those in countries like North America and Europe, enabling companies to reduce operational expenses while maintaining profitability.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

Leadgene Biosolutions expands product portfolio for metabolic research

Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Korea, Philippines to develop nextgeneration tuberculosis diagnosis

The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia and Indonesia achieve WHO Listed Authority status in medical products regulation

The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Aevice Health announces expansion into Australian market

AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO

Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia provides cheaper medicines for inflammatory & rare liver disease and MS

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement

France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal

Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy

Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.

time to read

1 min

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size